Management of chronic hepatitis B: An overview of practice guidelines for primary care providers

Journal of the American Board of Family Medicine

Volumn 28, Issue 6, 2015, Pages 822-837

  Han, Steven Huy ^a   Tran, Tram T ^b  

^a UCLA MEDICAL CENTER   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Chronic; Health care providers; Hepatitis B; Practice guideline; Primary health care

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA2B INTERFERON; TELBIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA; BIOLOGICAL MARKER;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ASYMPTOMATIC INFECTION; CANCER RISK; CHRONIC HEPATITIS B; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ELASTOGRAPH; ELASTOGRAPHY; HIGH RISK POPULATION; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MASS SCREENING; NON INVASIVE MEASUREMENT; PRIMARY MEDICAL CARE; RECURRENT VIRUS INFECTION; REVIEW; RISK ASSESSMENT; SERODIAGNOSIS; TREATMENT DURATION; BLOOD; CARCINOMA, HEPATOCELLULAR; COMPLICATION; HEPATITIS B, CHRONIC; LIVER NEOPLASMS; PRACTICE GUIDELINE; VIROLOGY;

ANTIVIRAL AGENTS; BIOMARKERS; CARCINOMA, HEPATOCELLULAR; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; MASS SCREENING; PRACTICE GUIDELINES AS TOPIC;

EID: 84946404158     PISSN: 15572625     EISSN: 15587118     Source Type: Journal    
DOI: 10.3122/jabfm.2015.06.140331     Document Type: Review

References (83)

1. World Health Organization. Hepatitis B. Fact sheet no. 204. Updated 2015. Available from: http://www.who.int/mediacentre/factsheets/fs204/en/. Accessed September 18, 2015.
2. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-128.
3. Ioannou GN. Hepatitis B virus in the United States: infection, exposure, and immunity rates in a nationally representative survey. Ann Intern Med 2011;154:319-28.
4. Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013;58:98-107.
5. Zoutendijk R, Reijnders JG, Zoulim F, et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut 2013;62:760-5.
6. Wong GL, Chan HL, Mak CW, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013;58:1537-47.
7. Lim YS, Han S, Heo NY, Shim JH, Lee HC, Suh DJ. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. Gastroenterology 2014;147:152-61.
8. Wu CY, Lin JT, Ho HJ, et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B-a nationwide cohort study. Gastroenterology 2014;147:143-51.e5.
9. Gordon SC, Lamerato LE, Rupp LB, et al. Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population. Clin Gastroenterol Hepatol 2014;12:885-93.
10. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2.
11. Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012;6:531-61.
12. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167-85.
13. Han SH, Jing W, Mena E, et al. Adherence, persistence, healthcare utilization, and cost benefits of guideline-recommended hepatitis B pharmacotherapy. J Med Econ 2012;15:1159-66.
14. Wu Y, Johnson KB, Roccaro H, et al. Poor adherence to AASLD guidelines for chronic hepatitis B management in a large academic medical center. Am J Gastroenterol 2014;109:867-75.
15. Burman BE, Mukhtar NA, Toy BC, et al. Hepatitis B management in Vulnerable populations: gaps in disease monitoring and opportunities for improved care. Dig Dis Sci 2013;59:46-56.
16. Juday T, Tang H, Harris M, Powers AZ, Kim E, Hanna GJ. Adherence to chronic hepatitis B treatment guideline recommendations for laboratory monitoring of patients who are not receiving antiviral treatment. J Gen Intern Med 2011;26:239-44.
17. Ku KC, Li J, Ha NB, Martin M, Nguyen VG, Nguyen MH. Chronic hepatitis B management based on standard guidelines in community primary care and specialty clinics. Dig Dis Sci 2013;58:3626-33.
18. Upadhyaya N, Chang R, Davis C, Conti MC, Salinas-Garcia D, Tang H. Chronic hepatitis B: perceptions in Asian American communities and diagnosis and management practices among primary care physicians. Postgrad Med 2010;122:165-75.
19. Les I, Garcia-Martinez R, Cordoba J, Quintana M, Esteban R, Buti M. Current trends in chronic hepatitis B management: results of a questionnaire. Eur J Gastroenterol Hepatol 2009;21:1177-83.
20. Ning LH, Hao J, Liao ZL, Zhou YY, Guo H, Zhao XY. A survey on the current trends in the management of hepatitis B in China. Eur J Gastroenterol Hepatol 2012;24:884-9.
21. Liang TJ. Hepatitis B: the virus and disease. Hepatology 2009;49:S13-S21.
22. Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int 2009;29(Suppl 1):100-7.
23. Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 2011;8:275-84.
24. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
25. Chan HL, Tse CH, Mo F, et al. High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 2008;26:177-82.
26. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006;101:1797-803.
27. Zaman A, Rosen HR, Ingram K, Corless CL, Oh E, Smith K. Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients. Am J Med 2007;120:280.e9-14.
28. Naveau S, Gaude G, Asnacios A, et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009;49:97-105.
29. Liaw YF. HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int 2009;3:425-33.
30. Chu CM, Liaw YF. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther 2010;15:133-43.
31. Chen YC, Chu CM, Liaw YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology 2010;51:435-44.
32. Funk ML, Rosenberg DM, Lok AS. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002;9:52-61.
33. Mitchell AE, Colvin HM, Palmer Beasley R. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology 2010;51:729-33.
34. Hatzakis A, Wait S, Bruix J, et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepat 2011;18(Suppl 1):1-16.
35. LeFevre ML; U.S. Preventive Services Task Force. Screening for hepatitis B virus infection in nonpregnant adolescents and adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;161:58-66.
36. Hu KQ, Pan CQ, Goodwin D. Barriers to screening for hepatitis B virus infection in Asian Americans. Dig Dis Sci 2011;56:3163-71.
37. Averhoff F. Yellowbook. Chapter 3: Infectious diseases related to travel. July 10, 2015. Atlanta: Centers for Disease Control and Prevention. Available from: http://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/hepatitis-b. Accessed September 18, 2015.
38. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2012;38:468-75.
39. Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010;52:176-82.
40. Schiff ER, Lee SS, Chao YC, et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol 2011;9:274-6.
41. Han K-H, Kim DY. Chronic HBV infection with persistently normal ALT b. not to treat. Hepatol Int 2008;2:185-9.
42. Chan HL, Chan CK, Hui AJ, et al. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Gastroenterology 2014;146:1240-8.
43. Comanor L, Minor J, Conjeevaram HS, et al. Impact of chronic hepatitis B and interferon-alpha therapy on growth of children. J Viral Hepat 2001;8:139-47.
44. Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol 2011;106:1264-71.
45. Liaw YF. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. Hepatology 2011;53:2121-9.
46. Huo TI, Wu JC, Lee PC, et al. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology 1998;28:231-6.
47. Wong PY, Xia V, Imagawa DK, Hoefs J, Hu KQ. Clinical presentation of hepatocellular carcinoma (HCC) in Asian-Americans versus non-Asian-Americans. J Immigr Minor Health 2011;13:842-8.
48. Tseng TC, Liu CJ, Yang HC, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012;142:1140-9.
49. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-14.
50. Heo J, Ahn SH, Kweon YO, et al. Entecavir + adefovir versus lamivudine + adefovir or entecavir alone in lamivudine-resistant chronic hepatitis B: 96-week data from the DEFINE study. J Clin Exp Hepatol 2013;3(Suppl):S60.
51. Jablkowski M, Diculescu M, Janssen HLA, et al. The safety and efficacy of entecavir and tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure. Hepatology 2013;58:711A (abstract 1044).
52. Zoutendijk R, Reijnders JG, Brown A, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology 2011;54:443-51.
53. Luo J, Li X, Wu Y, et al. Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naive chronic hepatitis B patients in real life. Int J Med Sci 2013;10:427-33.
54. Ko SY, Choe WH, Kwon SY, et al. Long-term impact of entecavir monotherapy in chronic hepatitis B patients with a partial virologic response to entecavir therapy. Scand J Gastroenterol 2012;47:1362-7.
55. Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res 2004;64:1-15.
56. Shouval D, Lai CL, Chang TT, et al. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol 2009;50:289-95.
57. Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 2010;139:491-8.
58. Petersen J, Buggisch P, Stoehr A, et al. Stopping long-term nucleos(t)ide analogue therapy before HBsAg loss or seroconversion in HBeAg negative CHB patients: experience from five referral centers in Germany. Hepatology 2011;54:1033A (abstract 1417).
59. Hadziyannis SJ, Sevastianos V, Rapti I, Vassilopoulos D, Hadziyannis E. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 2012;143:629-36.
60. Song MJ, Song do S, Kim HY, et al. Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B. World J Gastroenterol 2012;18:6277-83.
61. Petersen J, Buggisch P, Hinrichsen H, et al. Stopping long-term nucleos(t)ide analogue therapy before HbsAg loss in HbeAg negative CHB patients: follow-up of long-term responders. J Hepatol 2013;58:S313 (abstract 770).
62. Dusheiko G. Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues. Liver Int 2013;33(Suppl 1):137-50.
63. Chan HL, Wong GL, Choi PC, et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat 2009;16:36-44.
64. Wong GL, Wong VW, Choi PC, et al. Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases. Clin Gastroenterol Hepatol 2008;6:1027-35.
65. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335-52.
66. Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol 2015;62:956-67.
67. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
68. Wong VW, Chan SL, Mo F, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010;28:1660-5.
69. Yuen MF, Tanaka Y, Fong DY, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009;50:80-8.
70. Yang HI, Yuen MF, Chan HL, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol 2011;12:568-74.
71. Papatheodoridis G, Dalekos G, Sypsa V, et al. PAGE-B: risk score for hepatocellular carcinoma (HCC) development in Caucasian chronic hepatitis B (CHB) patients receiving entecavir (ETV) or tenofovir (TDF). J Hepatol 2014;60:S435 (abstract P1075).
72. Block TM, Gish R, Guo H, et al. Chronic hepatitis B: what should be the goal for new therapies? Antiviral Res 2013;98:27-34.
73. Matsuzaki T, Ichikawa T, Otani M, et al. The significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of HBV re-infection after liver transplantation. J Gastroenterol Hepatol 2013;28:1217-22.
74. Wong DK, Seto WK, Fung J, et al. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency. Clin Gastroenterol Hepatol 2013;11:1004-10.
75. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004;126:1750-8.
76. Bowden S, Locarnini S, Chang TT, et al. Impact of entecavir versus lamivudine on hepatic HBV covalently closed-circular DNA and total hepatic HBV DNA in nucleoside-naïve HBeAg positive chronic hepatitis B patients. J Hepatol 2013;58:S308 (abstract 759).
77. Takkenberg B, Terpstra V, Zaaijer H, et al. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir. J Gastroenterol Hepatol 2011;26:1527-35.
78. Cai D, Mills C, Yu W, et al. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother 2012;56:4277-88.
79. Chan HL, Thompson A, Martinot-Peignoux M, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol 2011;55:1121-31.
80. Lok AS, Trinh H, Carosi G, et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B. Gastroenterology 2012;143:619-28.
81. Sonneveld MJ, van Vuuren AJ, Verhey E, et al. Adding peginterferon alfa-2a to entecavir increases HBsAg decline and HBeAg clearance: first results from a global randomized trial (ARES study). Hepatology 2012;56(Suppl S1):199A (abstract 19).
82. Ning Q, Han M, Sun Y, et al. New treatment strategy: switching from long-term entecavir to peginterferon alfa-2a induces HBeAg seroconversion/HBsAg clearance in patients with HBeAgpositive chronic hepatitis B. Hepatology 2012;56(Suppl S1):300A (abstract 216).
83. Michel ML, Mancini-Bourgine M. Therapeutic vaccination against chronic hepatitis B virus infection. J Clin Virol 2005;34(Suppl 1):S108-14.